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Abstract32
Gender affirming treatment for transgender people requires a multidisciplinary approach in which33
endocrinologists play a crucial role. The aim of this paper is to review recent data on hormonal34
treatment of this population and its effect on physical, psychological and mental health. The Endocrine35
Society guidelines for transgender women include estrogens in combination with androgen lowering36
medications. Feminizing treatment with estrogens and anti-androgens has desired physical changes,37
such as enhanced breast growth, reduction of facial and body hair growth and fat redistribution in a38
female pattern. Possible side effects should be discussed with patients, particularly those at risk of39
venous thromboembolism. The Endocrine Society guidelines for transgender men include40
testosterone therapy for virilization with deepening of the voice, cessation of menses plus increase of41
muscle mass, facial and body hair. Due to the lack of evidence, treatment for gender non-binary people42
should be individualized. Young people may receive pubertal suspension, consisting of gonadotrophin-43
releasing hormone analogs, later followed by sex steroids. Options for fertility preservation should be44
discussed before any hormonal intervention. Morbidity and cardiovascular risk with cross-sex45
hormones is unchanged among transgender men and unclear among transgender women. Sex46
steroid-related malignancies can occur, but are rare. Mental health problems such as depression and47
anxiety have been found to reduce considerably following hormonal treatment. Future studies should48
aim to explore the long-term outcome of hormonal treatment in transgender people and provide49
evidence as to effect of gender affirming treatment in the non-binary population.50
Précis51
Review of original and recent data on hormonal treatment in transgender people, including their effect52
on physical and mental health53
54
55
Endocrinology of Transgender Medicine56
57
Introduction58
The acceptance by society, reflected in the media, that gender identity may not always match the59
assigned sex at birth, has provided the option and permission for individuals to question their gender60
identity more freely. Consequently, in some countries, transgender health services have expanded61
and developed so that gender diverse people wishing physical change are able to access gender62
affirming medical interventions. Hormone treatment, pivotal for those who wish to transition into their63
affirmed gender that differs from their sex that is assigned at birth, is ideally prescribed under the64
supervision of endocrinologists. However, many endocrinologists may feel uneasy and unskilled when65
working with the transgender population since the field of transgender medicine is relatively new. This66
paper aims to summarize the endocrine treatment for transgender people wishing to undergo gender67
affirmation therapies. The paper will first describe the terminology used in the field of transgender68
medicine, followed by a critical review of the diagnostic criteria currently in use, and summarize the69
mental health difficulties that transgender people may present with and the benefits of gender70
affirming treatment on wellbeing. Finally, the major focus of this paper will be to provide a critical71
review of the published literature on the hormonal treatment and long term monitoring for72
transgender children and adults.73
74
Terminology75
The term “gender non-conforming” is used to describe individuals whose gender identity, role or76
expression differs from what is normative for their assigned sex at birth in a given culture and historical77
period (1). Transgender is used as an umbrella term to describe individuals, whose gender identity78
differs from the assigned sex at birth. Transgender males are people assigned female at birth but who79
self-identify as male. Transgender females are people assigned male at birth, but who self-identify as80
female. When a person’s identity matches the sex assigned at birth, the term “cisgender” is used. The81
term “non-binary” describes people whose gender identity, role or expression does not conform to82
the binary understanding of gender (male or female). This can be used as an umbrella term to include83
people with no gender (agender), two genders (bigender), multiple genders (pangender), or with a84
fluid gender (gender fluid)(2,3), among others. Non-binary people prefer for people to use the85
pronouns of “they” and “them” when addressing them(3).86
Terminology changes all the time and terms used in the past may become outdated and can be87
perceived as pejorative. For example, the term transsexual which has been used since 1949(4), is88
largely now confined to the legal and medical literature. The International Classification of Diseases89
and Health Related Problems (ICD-10)(5) still uses the term “transsexualism” as a diagnostic term to90
describe individuals whose sex assigned at birth does not match their gender identity and wish gender91
affirming treatment. This term is likely to change to “gender incongruence” in the forthcoming 11th92
edition of the ICD(6). Other terms still used but considered outdated (although they can still be found93
in the literature) are: “FtM” (Female to Male) to describe transgender men or “MtF” (Male to Female)94
to describe transgender women.95
Gender dysphoria refers to a profound distress or discomfort caused by the discrepancy between a96
person’s assigned sex at birth and gender identity(1). Not every transgender person suffers from97
gender dysphoria and the urgency for medical intervention among transgender people may vary(1).98
For some people, social change may be enough without the need for further physical intervention. For99
others, due to their personal circumstances, physical intervention may not be opportune or100
appropriate. Many however, will access transgender health services in order to obtain gender-101
affirming treatment whether in the form of hormone treatment and/or through gender affirming102
surgery. Research in the field of transgender medicine has primarily focused on transgender people103
accessing transgender health services (7). Due to the requirement in certain countries, to provide104
funded health services only to those with a medical diagnosis, terms describing the gender related105
suffering of transgender people have remained part of current diagnostic criteria(5,8). In this106
manuscript, the term transgender will be used throughout to describe individuals who seek access to107
medical treatment in order for their bodies to become more congruent to their identified gender. A108
summary of some of the terms used in transgender health can be found in table 1.109
110
Methodology111
112
Eligibility criteria113
Studies were selected only if participants were described as transgender (whether self-identified or114
diagnosed by health professionals), and had empirical data relating to the hormonal treatment in this115
population. Only studies in English, published in peer reviewed journals and with more than ten116
participants were selected. This is a critical review with a focus on recent and original data. This paper117
describes and reviews the available literature since the last published review study by one of the co-118
authors of the current review(9).119
120
121
Information Sources and Search122
An electronic literature search was conducted between January 1999 and November 2017 using123
Medline/Pubmed, PsycINFO and Embase. Additionally, reference sections of identified articles and124
Google Scholar were examined for further relevant publications. The search used the following125
keywords: for terms referring to Transgender people (Transsexualism, transgender, Gender Dysphoria,126
Gender Identity Disorder, Trans*), for hormonal treatment, (cross-sex hormones, Testosterone,127
Estrogen, Blockers, GnRH agonist). Every term used for Transgender people was combined using the128
“OR” and the “AND” operate with every term used for Hormonal treatment. Articles of interest were129
those that included the transgender population and had empirical data relating to hormonal treatment130
within this population. Articles describing the effects of treatment, side effects, risk and long-term131
outcome were also collected and reviewed in order to help the discussion of the paper. If information132
was only to be retrieved from case reports, such as oncology, both the case reports and recent reviews133
on the specific topic were examined. The results of the review will be presented by describing the134
treatment in adults (transgender women and men) first followed by the treatment in adolescents.135
136
Diagnosis137
Currently the International Classification of Disease - version 10 (ICD-10) includes the diagnosis of138
transsexualism as part of the diagnostic category of “Gender Identity Disorders” (F64). It is expected139
that the new edition of the ICD (ICD-11) will change this term and move it out of the mental health140
chapter. It is likely that the new term to be used will be Gender Incongruence of Adolescence and141
Adulthood’ (GIAA)(6,10-11).142
The desire to de-pathologise being transgender and the importance of securing access to healthcare143
has been a dilemma in both the development of the DSM-5 and the new edition of the ICD (ICD-11).144
The American Psychiatric Association’s diagnosis in the current edition of the DSM (DSM-5), diagnoses145
the distress caused by the incongruence between assigned sex at birth and experienced gender as146
gender dysphoria. This diagnosis aims to classify the symptoms (dysphoria) and not the individual. For147
an individual to fulfill the diagnostic criteria for gender dysphoria they need to present with a marked148
incongruence between one’s experienced/expressed gender and assigned gender, of at least 6 months149
duration (APA(8)).150
If reaching a consensus to develop terms to classify transgender adults has been complicated, creating151
criteria for children has been even more complex. The ICD-11 is proposing the diagnosis of gender152
incongruence of children (10) while the DSM-5 uses the diagnosis of gender dysphoria in children.153
154
Prevalence155
More than 20 studies have aimed to investigate prevalence rates of transgender people. Although156
more recently prevalence rates of transgender identities have been reported using population studies,157
most of the available literature has extrapolated prevalence rates from people attending transgender158
health clinics (7).159
Some of the first epidemiological studies, which focused on individuals seeking services in order to160
undergo gender affirming genital surgery(12), found prevalence rates of 0.40 per 100,000 people. The161
ratio between male assigned at birth and female assigned at birth was found to be 4 to 1(11). Other162
European studies, based on people attending transgender health services, provide different163
prevalence rates over time; 1.22 per 100,000 (1976-1980), 1.58 per 100,000 (1976-1983), 2.77 per164
100,000 (1976-1986)(13). Once again rates of male assigned at birth transgender people have been165
found to be higher than female assigned at birth transgender people at a ratio of 3 to 1. Studies looking166
at more recent periods (between 1972 and 1996) provide higher prevalence rates of 3.42 per 100,000167
with ratios between birth assigned females and males being more similar (1.4 to 1)(14).168
Studies have also examined the number of people that have petitioned governmental agencies in order169
to change their gender status legally. Those studies have described prevalence rates ranging from 2.1170
(15) to 16.6 (16) per 100,000 people. A recent meta-analysis found an overall prevalence for171
transsexualism (as this is the diagnosis and term used in the published papers) of 4.6 in 100,000172
individuals; 6.8 for transgender women and 2.6 for transgender men with an increase in reported173
prevalence over the last 50 years(7).174
However, not every transgender person wishes and/or seeks medical care to affirm their gender(1). In175
order to identify the overall prevalence of transgender people (including those not accessing services)176
population studies may be more representative of the transgender community. Population based177
studies have found a considerably higher prevalence rate than those reported in clinical studies. For178
example, a study asking a sample of community participants in the United States (28,045 aged 18-64)179
as to whether they considered themselves transgender found a prevalence rate of 0.5% (17). Studies180
from the Netherlands and Belgium described that 0.7%(18) and 1.1%(19) of people assigned male at181
birth and 0.6%(18) and 0.8%(19) of people assigned female at birth reported an incongruent gender182
identity.183
The majority of the epidemiological studies have been conducted in Western countries, particularly in184
Europe and the United States. Societies which are more egalitarian and open will facilitate the185
expression of gender diversity, hence prevalence rates in those countries may be reported higher than186
in more restrictive societies. Low prevalence rates in certain societies may need to be regarded with187
caution as it may reflect a symptom of repression. A ban on gender identity expression for personal,188
cultural or religious reasons, may manifest itself as distress and profound unhappiness and may lead189
to the development of mental health problems(20).190
191
Mental health in transgender people and effect of hormonal treatment192
Overall prevalence of mental health diagnoses193
Studies investigating rates of mental health diagnoses in the transgender population, once again, have194
focused on those attending transgender health services(21). Most of the studies have been cross-195
sectional and report high rates of affective disorders (38%)(22) such as depression(23) and adjustment196
disorders(24) as well as anxiety disorders (17%)(25,26). Young transgender people are found to have197
high rates of non-suicidal self-injuries have also been found to be very high, particularly among young198
people (46%) as well as suicide attempts(27,28,29). The few studies that compared their findings to199
the general cisgender population (controlled by age and sex) found certain mental health diagnoses,200
such as anxiety disorders, are 3 times more prevalent among transgender people compared to201
cisgender people(25).202
Differences in prevalence according to gender203
There are some discrepancies as to whether mental health diagnoses are more common among204
transgender men or among transgender women. Some studies have found mental health diagnoses205
were not related to assigned or identified gender(30,31), while other studies have demonstrated206
higher rates of mood disorders(23,32), anxiety disorders(32), adjustment disorders(18), and substance207
abuse(24) among transgender women than transgender men. Most of those studies are biased by not208
controlling for factors known to influence mental health diagnoses, particularly hormone treatment.209
This means that people have been recruited for studies independently as to whether they are on210
hormone treatment or not, while research has confirmed that such treatment reduces mental health211
problems. Interestingly, more recent large controlled studies involving only transgender people not on212
treatment have found anxiety disorders were more prevalent among transgender men than among213
transgender women(25). A similar study also found levels of self-harm were also higher among the214
same group(28).215
Predictors of mental health problems216
Several factors have been found to predict mental health issues among the transgender population217
attending transgender health services, such as experiences of victimization (or transphobic218
experiences), low self-esteem(27), and interpersonal problems(28,33). Lack of hormone treatment for219
those wishing physical change has been found to be the strongest predictor of mental health220
diagnoses(21,25,31).221
The role of hormone treatment in mental health222
A number of longitudinal studies have explored the role of hormonal treatment in mental health and223
quality of life among transgender people wishing gender affirmation treatment. These studies, which224
have mainly been conducted in Europe (Sweden(34), Italy(35), Belgium(36) or Germany(37)), have all225
demonstrated that people’s mental health (levels of depression and anxiety) significantly improved226
following hormone treatment. Long-term follow-up studies and studies involving large groups of227
people are needed to evaluate whether these improvements remain. Hence, hormone treatment for228
those wishing physical change needs to be accessible, as this will reduce morbidity and improve quality229
of life of transgender people.230
231
Post treatment regrets232
The literature in posttreatment regret is complex to interpret. Overall satisfaction post gender-233
affirming treatment is high. A study from more than 20 years ago found 2% of transgender women and234
1% of transgender men later regretted their decision to undergo hormonal and/or surgical treatment235
(38). There are many causes of regret. Frequently dissatisfaction following gender affirming surgery236
has been interpreted as regret regarding social and medical transition. In order to distinguish those237
people who express dissatisfaction following gender affirming treatment, from those who wish to de-238
transition and return to their sex assigned at birth, Pfäfflin (1993) differentiates minor from major239
regrets. In one of the largest gender clinics (Amsterdam), 2034 individuals received treatment between240
1975 and 1998. Ten of these people subsequently indicated that they regretted their decision to have241
undergone the treatment (nine transgender women and one transgender man)(39). The reason for242
those regrets varied from identifying with the sex assigned at birth and wanting de-transition (n=6)243
(classified as major regrets) from dissatisfaction of the outcome of surgery or loss of support following244
gender affirming treatment (n=4) (minor regrets). Upon review in 2005 the number of major and minor245
regrets increased by five out of a total of 3090 subjects. In 2015 the total number of subjects treated246
had risen to 6793 but there was no further increase in those expressing regret. The fact that fewer247
people have been having doubts about their treatment decisions over time may reflect the much-248
improved understanding of gender incongruence both by transgender people themselves and by the249
medical profession, as well as much greater acceptance of transgender people in society(39).250
Summary251
Mental health diagnoses are common in the transgender population, possibly due to negative societal252
values, but do improve once gender affirming treatment is initiated. This highlights the importance of253
hormone treatment and access to adequate transgender healthcare. Although state funded health254
services, which are primarily available in Europe, may develop services where the needs of the255
transgender population can be provided for, including assessment, psychological support (if needed),256
hormonal treatment and gender affirming surgery, other healthcare systems may not be so fortunate257
and transgender people may find themselves searching for professionals who are able to confidently258
prescribe and monitor hormone treatment.259
260
261
Results262
I. Hormonal treatment in transgender women263
264
Initial evaluation of transgender women265
Transgender women seek hormone therapy to change their physical appearance to better match266
their gender identity and expression(40,41). Furthermore, transgender women experience improved267
quality of life and decrease in gender dysphoria upon initiation with hormone therapy(42,43). In the268
United States, Canada and most of Europe, transgender women must seek medical professionals for269
hormone therapy since these medications are available only by prescription but there is a black270
market also particularly for oral contraceptives. For non-Western countries, hormone therapy is271
often self-prescribed without supervision by a medical professional. Available evidence from the272
United States and Europe suggest that hormone therapy initiated and monitored under the273
supervision of a medical professional is associated with very low rates of adverse events(44,45).274
The Endocrine Society guidelines recommend that a medical professional confirms the diagnosis of275
gender dysphoria and/or gender incongruence in transgender women prior to the initiation of276
hormone therapy. Medical professionals should document that the gender dysphoria has been277
persistent and that the individual is able to make an informed decision and consent for278
treatment(40). However, there are no validated psychological tests or imaging studies that have279
been clinically useful to diagnose gender dysphoria(46), this is likely due to the fact that people with280
gender non-conforming expression and behaviors represent a very large and heterogeneous281
population. There is no demonstrable biological substrate for gender incongruence. In this regard,282
medical professionals have been moving towards a more gender affirmative model whereby the283
medical professional provides a more patient centered approach to care and understands the needs284
of the person rather than making a diagnosis of the patient(47,48).285
286
Screening for conditions prior to initiation of hormone therapy287
Medical professionals should evaluate transgender women for conditions that can be exacerbated by288
hormone therapy. History of thromboembolic diseases such as deep vein thrombosis and pulmonary289
embolism should undergo evaluation and treatment prior to the initiation of hormone therapy(40).290
In addition, risk factors that can increase the risk of thromboembolic conditions should be modified291
such as smoking, obesity, and sedentary lifestyle. In patients with modifiable risk factors such as292
known thrombophilia, past history of thrombosis, or strong family history of thromboembolism,293
treatment with transdermal estrogen and/or concomitant treatment with anti-coagulation therapy294
may need to be considered; although there are limited data to guide treatment decisions (49,50).295
Other diseases such as hormone sensitive cancers, coronary artery disease, cerebrovascular disease,296
hyperprolactinemia, hypertriglyceridemia, and cholelithiasis should be evaluated prior to the297
initiation of estrogen therapy as these conditions can be exacerbated by estrogen.298
299
Modalities of hormonal therapy in transgender women300
There are two main classes of medications used in transgender women: 1) estrogens and 2)301
androgen lowering hormones therapies.302
303
Estrogen Therapies304
The synthetic estrogen ethinyl estradiol was a widely used estrogen in Europe prior to 2003.305
However, given recent safety concerns about its pro-thrombotic potential and its potential role in306
cardiovascular disease, most clinics have now switched to oral, cutaneous or intramuscular307
estradiol(51). A few commonly used estrogen regimens in transgender women have been reported308
(Appendix B of reference 40); however, there are very few head to head studies comparing the309
efficacy and safety of estrogen regimens. In a large multi-national cohort study (entitled European310
Network for the Investigation of Gender Incongruence (ENIGI)) of 4 European countries (Belgium,311
The Netherlands, Italy and Norway), over 300 transgender women were prescribed oral estradiol312
valerate 4 mg daily or estradiol valerate 20 mg intramuscularly every two weeks or estradiol patch313
100 mcg daily, each with cyproterone acetate (CPA) 50 mg daily(52). In the short-term (< 5 years),314
these regimens are associated with mild elevations of prolactin(53) and improvements in bone315
mineral density after 1 year of therapy (54). No short- or long- term adverse events have been316
published from this cohort using this hormone regimen.317
In a German cohort, transgender women were treated with a regimen of estradiol valerate 10 mg318
intramuscularly every 10 days. The authors also report short term gains in bone density after 24319
months of therapy along with higher BMI with an increase of fat mass and decrease of lean body320
mass(55).321
In the United Kingdom, transgender women were previously prescribed ethinyl estradiol or322
conjugated equine estrogen are now changed to oral estradiol at a dose of approximately 4 mg323
daily(56). In a retrospective review of transgender women in the UK, transgender women prescribed324
oral conjugated equine estrogens had increased risk of thromboembolism compared to transgender325
women taking oral estradiol valerate or ethinyl estradiol. In this cohort, 4.4% of transgender women326
on oral conjugated equine estrogen experienced a thromboembolic event compared to <1% in327
transgender women or estradiol or ethinyl estradiol (p=0.026).328
In the United States, estrogen therapy can be prescribed as oral tablets, intramuscular injections, and329
transcutaneous preparations(41). Most commonly published in the United States is the prescription330
of oral estradiol 4-5 mg daily(57,58). Studies that compare the long-term safety and effectiveness331
among the different formulations of estrogen are lacking. The Endocrine Society Guidelines332
recommend that the doses of estradiol be titrated to serum estradiol levels around 200 pg/mL (734333
pmol/L)(40).334
335
Androgen Lowering Therapies336
Transgender women will often require the addition of a medication to lower testosterone levels into337
the female range(59). In most European countries, the most commonly prescribed androgen338
lowering medication is oral CPA 50 mg daily (44,52,60). Cyproterone acts primarily as an androgen339
receptor blocker but also has some progesterone like activity(61). However, given reports of340
increased risk of meningiomas(62-64), association with depression(56), and increased risk of341
hyperprolactinemia(53) with CPA use, in the United Kingdom (UK), transgender women are now342
prescribed gonadotropin-releasing hormone (GnRH) agonists to lower testosterone343
concentrations(65). In contrast to the rest of Europe and the United States, GnRH agonists are344
provided free of charge to transgender women by the National Health Service in the UK (56).345
Spironolactone is the most commonly prescribed testosterone lowering medication in the United346
States(57,58). Spironolactone is classically known as an antagonist of the mineralocorticoid receptor347
and a potassium sparing diuretic. It also has anti-androgen properties by directly lowering348
testosterone synthesis and testosterone action at the androgen receptor(40). One U.S. cohort of349
about 100 transgender women found estrogen therapy in combination with oral spironolactone 200350
mg daily was effective in lowering serum testosterone levels in to the cisgender female range for351
serum testosterone after about 1 year of therapy(66).352
Peripheral androgen receptor blockers such as flutamide or dutasteride have not been353
recommended for use in transgender women since these agents do not lower serum testosterone354
levels and there are limited published studies in this population(40).355
356
Other Second Line Hormonal Therapies357
Progesterone358
Progesterone therapies such as medroxyprogesterone have been used as a second agent to lower359
testosterone concentrations in transgender girls and women(57). Some transgender women may360
request progesterone to enhance breast development; however, there are no clinical studies to361
support a positive effect of progesterone on breast development(67). Furthermore, there are362
concerns regarding potential increased risk of thromboembolism and stroke found in cisgender363
women taking progesterone(68,69). Therefore, progesterone therapy is not a routinely used364
medication in transgender women.365
366
5α-Reductase Inhibitors 367
Some transgender women may experience male pattern hair loss and may seek treatments to arrest368
hair loss and/or restore hair. In general, lowering serum testosterone levels into the cisgender369
female range is often adequate to arrest hair loss in most transgender women; however, there are370
still some transgender women who experience hair loss despite lowered serum testosterone levels.371
A few case series in transgender women with androgenetic alopecia have demonstrated finasteride372
therapy to be effective to improve hair loss without significant side effects(70,71). The routine use of373
5α-reductase inhibitors has been limited over previous concerns of long-term sexual dysfunction and 374 
depression reported to be found in cisgender men(72,73).375
376
Feminization in transgender women377
Treatment with estrogen and testosterone lowering medications will induce feminine and reduce378
masculine physical characteristics. The most studied physical change in transgender women is the379
development of breast tissue. An Italian cohort study found increases in breast size were the only380
physical feature that was significantly associated with improvement in body uneasiness scores(43).381
However, less than 20% of transgender women reach Tanner Breast stage 4-5 after 24 months of382
hormone therapy and thus often seek mammoplasty. Early studies in transgender women indicated383
breast development reached a maximum size by 2 years(74). However, a more recent study of 229384
transgender women participating in the ENIGI cohort found breast development reached a plateau385
within the first 6 months of therapy and half of the transgender women had a AAA cup size or386
less(75). Fisher and colleagues also found testicular volume decreased by approximately 60% after 24387
months of transfeminine hormone therapy(43).388
389
Body composition390
A meta-analysis of studies published prior to 2015, transfeminine hormone therapy was associated391
with increased body fat and decreased in lean body mass in 171 transgender women(76). More392
recent studies from Europe have documented that BMI increases in transgender women after393
transfeminine hormone therapy(43,77). Klaver et al also demonstrated increases in body weight in394
179 transgender women and transfeminine hormone therapy was associated with in increase in body395
fat, specifically in the android, leg and gynoid regions (78). However, recent studies from the USA396
have demonstrated that significant changes in BMI in transgender girls and women do not occur over397
a short term (< 6 months)(56,79).398
399
Voice400
Transgender women will have improved self-perceived feminine quality in their voice after the401
initiation of hormone therapy(80). However, many transgender women still have difficulty with their402
voice quality and are misperceived in the wrong gender by others(81). Transgender women may403
undergo voice training exercises to improve their voice quality(82). Laryngeal surgical treatment has404
been described as an option for transgender women to improve voice quality; however, a meta-405
analysis failed to demonstrate significant benefit of surgical techniques to improve the quality of the406
voice(83).407
408
Skin and Hair409
Transgender women will also experience reduction in facial hair after transfeminine hormone410
therapy. Fisher et al reported that Ferriman and Gallwey scores improved after two years of411
transfeminine hormone therapy(43). Transfeminine hormone therapy may arrest male pattern hair412
loss(71). A survey of transgender women reported interest in having facial hair removal procedures413
however very little data on the effectiveness of such procedures have been published(84).414
415
Safety data specific to transgender women416
417
1. Cardiovascular and thromboembolic safety418
There have been some concerns about long-term effects of transfeminine hormone therapy on419
cardiovascular outcomes. A single center study of over 200 transgender women from Belgium420
reported increased rates of myocardial infarction, venous thrombosis, and cerebrovascular disease421
compared to cisgender men and women(85). A recently commissioned systematic review and meta-422
analysis of cardiovascular outcomes in transgender individuals did not find an increased risk of423
myocardial infarction, stroke or venous thrombosis in transgender women due to lack of reported424
outcomes from 29 eligible studies(86). This systematic review also found transfeminine hormone425
therapy was associated with increased serum triglyceride levels of 31.9 mg/dL (95% CI: 3.9 to 59.9) in426
transgender women treated for greater than 24 months with no changes in serum LDL or HDL.427
Thrombosis risk in transgender women is likely increased given the known pro-thrombotic actions of428
estrogen. However, under medical supervision, the risks of transfeminine hormone therapy appears429
to be safer than self-prescribed transfeminine hormone therapy(45). A large study conducted in 162430
transgender women treated with transdermal estrogen in Austria found only 19 had a genetic431
mutation associated with venous thrombosis (1 protein C deficiency and 18 with activated protein C432
resistance) and none developed a thrombotic event, suggesting that estrogens that avoid the hepatic433
first pass effect may have less pro-thrombotic risk (87). Furthermore, given the low frequency of434
genetic mutations associated with thrombosis (19 out of 162), the authors do not recommend435
routine screening for thrombophilia. There have been reports of transgender women who436
developed a thrombotic event and successfully treated with anti-coagulation therapy (88,89).437
However, there are no long time studies to guide treatment for transgender women following a438
thrombotic event.439
440
2. Bone Health441
The fracture rate associated transfeminine hormone therapy is unknown. Estrogen is critically442
important for preserving bone mineral density in post-menopausal women and in men who lack443
estrogen action at the bone, (e.g. mutations in the estrogen receptor or aromatase enzyme)(90,91).444
A recent meta-analysis of 392 transgender women found a significant increase in lumbar spine bone445
mineral density but no changes in hip bone mineral density. The rates of fracture were found to be446
low with no fractures found in 53 transgender women after 12 months in this review(92). A recent447
multi-center study of 231 transgender women in Europe treated with transfeminine hormone448
therapy found a 3.67% increase in lumbar spine bone density and a 0.97% and 1.86% increase in total449
hip and femoral neck bone density, respectively, after 1 year of therapy(54).450
Transgender women have been found to have lower bone mineral density even prior to the start of451
hormone therapy(93). Van Caenegem and colleagues found 16% had T-scores at the lumbar spine <-452
2.5 and approximately one third of transgender women had T-scores between -1 and -2.5 at the453
lumbar spine or total hip. The reasons why transgender women had lower bone density than454
expected for age is not clear but the authors hypothesize decreased outdoor physical activity as455
vitamin D status was found to be low in 72% of the cohort.456
457
3. Oncological data and mortality458
The prevalence of hormone sensitive cancers such as breast and prostate cancer appears to be low459
among transgender women. Initial studies from a cohort of over 2000 transgender women reported460
no increase in breast cancer incidence compared to the expected rate of breast cancer in cisgender461
women(94). A large cohort of over 5000 transgender military veterans in the USA reported only 9462
cases of breast cancer in transgender veterans, two in transgender women and seven in transgender463
men(95). All of the transgender women presented with late stage breast cancer that proved to be464
fatal, whereas the transgender men before or after breast ablation presented with earlier465
disease(96). One the largest studies examining cancer risk in transgender women in the USA utilized466
data from one large healthcare system (Kaiser Permanente: Georgia, Northern and Southern467
California (97). Using an electronic database method to identify transgender women in this cohort,468
they identified 2791 transgender women subjects. Based on ICD-9 codes, the investigators found no469
increased risk of breast cancer or any cancer compared in transgender women to matched cisgender470
women. However, there was an increased risk of breast cancer and endocrine gland cancers in471
transgender women compared to matched cisgender men. Furthermore, there was a decreased risk472
of prostate cancer compared to matched cisgender men. Other studies have reported a low risk of473
prostate cancer in transgender women. A recent review of literature of prostate cancer in474
transgender women only found 10 cases reported(98).475
476
Other Considerations477
Fertility478
All transgender women should be aware of the potential fertility preservation options such as sperm479
cryopreservation. Transgender women report that they are interested in having their own biologic480
children but very few transgender women utilize fertility preservation technologies(99,100), possibly481
due to the lack of funding for fertility preservation in many countries. Since sperm production will482
decline after the initiation of hormone therapy, the Endocrine Society guidelines recommend that all483
transgender women discuss fertility options with their healthcare team prior to the initiation of484
hormone therapy (40).485
486
Monitoring of feminizing hormone therapy487
Transgender women who take hormone therapy under medical supervision experience very low488
rates of complications (44,45). Transgender women should maintain serum estradiol and489
testosterone concentrations within the expected physiologic female range (40). The Endocrine490
Society recommends hormone measurements every 3 months in the first year of initiating hormone491
therapy until the hormone concentrations reach the desired concentrations. Once the hormone dose492
is achieved, the hormone concentrations of both testosterone and estrogen can be measured once493
yearly or when there is a dose change to ensure that levels remain in the range expected for494
cisgender females (40). Transgender women taking spironolactone should have measurement of495
potassium and kidney function on a regular basis. Following surgery, transgender women can have a496
final measurement of serum testosterone to confirm levels in the male range are eliminated.497
Measurement of prolactin levels during the course of gender affirming hormone therapy has been498
suggested by the Endocrine Society guidelines. However, recent reports indicate that elevated499
prolactin levels seem to occur in transgender women on cyproterone acetate and not on500
spironolactone. Defreyne et al demonstrated that prolactin levels increased in transgender women501
receiving cyproterone but decreased after discontinuation (101). Furthermore, a recent study by502
Fung et al demonstrated that transgender women treated with cyproterone had significant higher503
prolactin levels compared to those treated with spironolactone (102).504
505
Insert Fig. 1 about here506
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II. Hormonal treatment in transgender men510
Initial evaluation of transgender men511
During the first outpatient consultation, the same principles apply as described for transgender512
women above.513
514
Screening for conditions prior to initiation of hormone therapy515
Transgender men must be informed on the possibilities, consequences, limitations and risks of516
testosterone treatment. Fertility preservation options are to be discussed before starting a medical517
intervention. Pregnancy is an absolute contraindication for testosterone therapy, and relative518
contraindications include severe hypertension, sleep apnea and polycythemia(40). Conditions that519
can be exacerbated by testosterone therapy are presence of erythrocytosis, baseline high hematocrit520
levels (e.g. secondary to smoking or COPD), sleep apnea and congestive heart failure. Knowledge on521
the presence of menstruation problems prior to initiation of testosterone treatment and on sexual522
practices will guide the need for follow-up procedures such as pelvic ultrasounds and pap smears.523
524
Modalities of hormonal treatment in transgender men525
Testosterone526
The principal hormonal treatment used to induce virilization is testosterone. Under medical527
supervision, testosterone therapy is safe based on short and longer-term safety studies(44,103,104).528
Different testosterone formulations may be available depending on geographical location. Most529
commonly prescribed are injectable testosterone esters (40). More recently subcutaneous530
administration of testosterone was shown to be effective and preferred by transgender men at a531
median dosage 75 mg weekly in 63 transgender men (105,106), confirming an earlier intervention532
study (106). Long acting testosterone undecanoate is also being used for treatment of transgender533
men (107). However, in the United States, the prescription of testosterone undecanoate is limited534
due to the potential risk of oil pulmonary embolus and both patient and provider must undergo Risk535
Evaluation and Mitigation Strategy (REMS) training to receive this therapy. Other intervention536
studies (Appendix A of reference 40) have also used topical androgen gel or transdermal patches.537
The use of oral testosterone (testosterone undecanoate), axillary solutions, patches, nasal sprays,538
buccal tablets or pellets is rarely reported for treatment in transgender men. In one study the effects539
of three different testosterone formulations were evaluated at baseline and after 12 months of540
treatment and no differences were found regarding short-term safety, compliance, body541
composition, metabolic parameters and general life satisfaction (108). Androgen therapy will need to542
be continued lifelong to maintain the achieved virilization and to avoid symptoms of hypogonadism543
such as vasomotor symptoms or osteoporosis.544
Progestational agents545
If menstrual bleeding does not stop after initiation of testosterone, a progestational agent, such as546
oral lynestrenol 5-10 mg daily or medroxyprogesterone 5-10 mg, might be considered. This occurs547
frequently with the use of transdermal or oral testosterone undecanoate, which are both associated548
with lower testosterone levels compared to injectable testosterone. GnRH analogs to halt menses549
are theoretically possible, but rarely reported in adults given the costs of therapy. If ovariectomy is550
performed, the progestational medication can be discontinued (109-111).551
552
Virilization in transgender men553
Treatment in transgender men is intended to induce virilization. This includes cessation of menses,554
development of male physical contours, a deepening of the voice, clitoral growth, increased sexual555
desire and increased facial and body hair(110,112,113). Male-pattern baldness may also occur.556
Changes in body composition; with redistribution of body fat, increased muscle mass and strength557
have been described extensively (40,44,114). The time period before cessation of menses may vary558
from 1-12 months after testosterone initiation, sometimes requiring the addition of a progestational559
agent (40,115). Mean clitoral length may reach 3.83 +/- 0.42 cm after 2 years of testosterone therapy560
(43)561
It is important that transgender men understand the possibilities but also the limitations of562
testosterone treatment. Height and bone structure (broader hips) and the larger degree of563
subcutaneous fat remain largely unchanged when therapy is started after puberty(110). Most of the564
published guidelines have been developed with the Caucasian transgender person in mind, but565
ethnic differences may warrant tailoring of standard doses (116). Recommendations based on clinical566
experience are in favor of continuing testosterone treatment for elderly transgender men(117).567
Body composition568
Testosterone therapy will enhance a more masculine musculature, body shape and body fat569
distribution. Testosterone therapy will result in changes in body composition. A meta-analysis of 10570
studies examining body composition changes in response to testosterone over 12 months found571
body weight increased by +1.7 kg (0.7-2.7), body fat decreased by 2.6 kg (-3.9; -1.4) and lean body572
mass increased by +3.9 kg (3.2; 4.5) (76). Another systematic review, focusing among other573
parameters on BMI, revealed an increase in BMI from 1.3 to 11.4% (118). Grip strength increased574
with 18% in a study with 23 participants and one-year parenteral testosterone undecanoate575
treatment (93).576
Voice577
Testosterone therapy at doses in the physiological range for men will induce acoustic changes578
occurring from effects on the larynx (119). In a cross-sectional study of 38 transgender men, acoustic579
voice variables and voice quality was similar between the transgender men and cisgender controls.580
However, 10% of the transgender men experienced issues with pitch quality, needing voice therapy581
and sometimes pitch-lowering surgery (120). Transgender men (n = 77) whose voices sounded more582
congruent with their experienced gender reported greater well-being than those with less gender583
congruent voices (121). There is very little prospective data on the voice changes in transgender men584
upon testosterone treatment. Seven transgender men on intramuscular testosterone esters, all585
reached a cisgender male mean fundamental frequency within 6 months of testosterone therapy. A586
mean decrease of 49 Hz was measured (122). In the largest longitudinal study to date (n = 50, with 36587
having data for baseline and 12-month follow-up) acoustic analysis of fundamental frequency of the588
habitual voice showed a significant decrease after 3 (- 37 Hz), up to 12 (-67 Hz) months, with group589
data congruent with cisgender male reference data. In 24% of participants additional voice therapy590
was necessary. When using an adapted version of the transsexual voice questionnaire (123) for591
transgender men (TVQMtF) looking at self-perception of voice prospectively during intramuscular592
testosterone undecanoate therapy in 80 participants, improvements during the first 3 months were593
attributed to the hormonal intervention (80).594
Skin and hair595
Both androgens and estrogens are known to affect the pilosebaceous unit of the skin, as in the596
sebocytes and hair follicle dermal papilla androgen and estrogen receptors are expressed. In a study597
of 17 transgender men, intramuscular testosterone therapy was associated with increases in the598
Ferriman-Gallwey hirsutism scores (124). After 12 months facial and abdominal hair had not yet599
reached diameters found in cisgender males. An increase in acne on the face and back was present in600
94% and 88% after four months, respectively. Data on both shorter and longer term dermatological601
effect of IM testosterone undecanoate were available from a prospective intervention study in 20602
hormone naïve transgender men, combined with a cross-sectional part with 50 transgender men603
with an average of 10 years on various testosterone treatments (103). The Ferriman-Gallwey score604
(in cisgender women usually <8) increased in a time –dependent manner from median 0,5 to 12 after605
one year, while long-term testosterone treatment resulted in a median score of 24. The presence606
and severity of acne based on the Gradual Acne Grading Scale increased during the first year and607
peaked at 6 months; facial acne was present in 82%, and back acne was present in 88%. Long-term608
data from this study showed 94% of transgender men had no to mild acne. In a study with 45609
transgender men, 16% developed troublesome acne when treated with testosterone undecanoate610
for two years (125).611
In a retrospective, observational study 81 transgender men treated with testosterone esters or612
testosterone undecanoate self-assessed the degree of male pattern baldness (MPB) using a five-613
point scale (i.e. type I (no hair loss) to type V (complete hair loss)). The authors found 38% of614
transgender men had MPB type II-V. Thinning of hair was related to the duration of androgen615
administration and present in half of the transgender men after 13 years (126). Wierckx et al616
reported that (44), 17% of participants developed androgenic alopecia based on the Norwood-617
Hamilton classification after 1 year of treatment. Longer-term (10 years on average) testosterone618
treatment was associated with 32% of mild frontotemporal hair loss and 31% moderate to severe619
androgenetic alopecia (103). In 10 transgender men with androgenetic alopecia, treatment with oral620
finasteride 1 mg daily for 12 months, induced improvement with one grade on the Norwood-621
Hamilton scale after a mean of 5,5 months since the start of treatment (70).622
623
624
Safety data specified for transgender men625
1. Cardiovascular safety626
Adult cisgender men have higher cardiovascular mortality rates than women, which has been627
attributed to differences in sex hormone levels. However, the available cardiovascular outcome data628
in transgender men show that testosterone treatment does not result in adverse cardiovascular629
outcomes(127). Four different recent review papers (86,118,128,129) summarized the effects of630
testosterone on surrogate risk factors of cardiovascular disease. These studies demonstrated despite631
a perceived negative impact on a number of risk factors including an increase in hematocrit, a632
decrease in high-density lipoprotein cholesterol, increase in triglycerides, low-density lipoprotein633
cholesterol levels, and inflammation parameters (130), small increase in systolic blood pressure634
(44,125), decrease in adiponectin and leptin (131) no significant increase in cardiovascular outcomes635
(77). Furthermore, there have been no elevated rates of cardiovascular deaths when compared with636
cisgender men and women at short and medium follow-up in the larger studies (except for one study637
(30)). However, data on cardiovascular outcomes in older (65+ years) transgender men are mostly638
lacking (86). In a cross-sectional study of 50 transgender men on testosterone treatment for an639
average of 10 years, no subject had experienced myocardial infarction, stroke or deep venous640
thrombosis (132). In a similar case-control study 138 transgender men 7.4 years on average on641
testosterone therapy showed a low cardiovascular morbidity (85). In a prospective study with 43642
transgender men, who were treated with testosterone esters every 3 weeks, there was an increased643
incidence of previously absent metabolic syndrome after 1 (16,3%) and 2 years (18,6%), especially in644
those with psychiatric comorbidity(133). Furthermore, most studies in transgender men report no645
adverse impact of testosterone treatment on fasting glucose or insulin sensitivity (44,108,131,133).646
Many studies report an association between testosterone therapy and increased hemoglobin (+ 4.9-647
12.5% range) and hematocrit (+ 4.4-17.6% range) during the first year of treatment, which then648
plateaus after the initial year of treatment (107,125). Clinically significant erythrocytosis has been649
reported but is likely very uncommon (118). In such cases, practitioners sometimes advise change of650
the testosterone route of administration or reduction of dosage, despite the absence of outcome651
data showing risk reduction of thrombotic events. In one study use of testosterone gel showed652
smaller increases in hemoglobin (+4%) and hematocrit (+2%) compared to injectable653
testosterone(108).654
A prospective study of 89 transgender men treated with parenteral testosterone undecanoate and655
lynestrenol for about 4 years found no cases of venous thromboembolic disease despite 5 subjects656
who had the activated protein C mutation. The authors concluded that general screening for657
thrombophilic defects is not recommended (134). In a similar study, fifty transgender men followed658
for about 10 years found no cases of venous thromboembolism (132)659
It is important to stress that most transgender men are still relatively young, at an age when the risk660
of cardiovascular events is low. Long-term data and data from older transgender men are needed.661
2. Bone health662
Sex steroid hormones play important roles in bone growth and maintenance. Men develop larger,663
longer and stronger bones during puberty, explained through the combination of sex steroids and664
mechanical loading. Testosterone therapy in transgender men preserves bone density with adequate665
dosing due to aromatization of testosterone to estradiol (135). There are very limited data on the risk666
of osteoporotic fractures in transgender men (92). Transgender men have similar BMD compared to667
cisgender females prior to testosterone therapy (93,136,137).668
Following ovariectomy, testosterone substitution therapy appears to prevent short term (<2 years)669
(54,93,108,125,136,138-140) and long term (10 + years) (141-143) bone loss due to estrogen670
deficiency. Transgender men have larger cortical bone size compared to cisgender females in a cross-671
sectional study (143). An additional study confirmed the higher cortical thickness by672
histomorphometric bone biopsy study (145) and higher aBMD at cortical sites (139,142). This reflects673
the effect of androgens on the periosteal circumference of cortical bone. The androgen-induced674
higher muscle mass also induces a higher mechanical load on the bone, possibly stimulating bone675
formation according to the mechanostat theory (146). Higher bone formation was observed in676
transgender men on testosterone (93,136,141,143) and both muscle mass and strength were677
positively associated with trabecular and cortical parameters and bone size. Nearly all studies reported678
a maintained aBMD, which argues against bone loss (92). However, in transgender men who679
underwent ovariectomy, bone loss has been described when they irregularly used or stopped680
androgen therapy or when dosage was inadequate (137,138,141).681
3. Oncological data and mortality682
Both practitioners and transgender men express concern around carcinogenicity of long-term683
hormonal therapy, although these concerns are not supported by the available data. Recently the684
published cancer case reports in transgender men were summarized (147): 1 vaginal, 1 cervical, 7685
breast, 3 ovarian and 1 endometrial cancers have been described to date. The association to risk686
factors such as smoking and alcohol use, sexually transmitted infections and lack of adequate access687
to screening programs has to be acknowledged and be included in future research (147). In688
transgender men on testosterone treatment and not undergoing surgical interventions, breast and689
cervical cancer screening protocols are advised, but timing and frequency of monitoring of female690
internal organs in transgender men are a matter of debate.691
692
The available data on cancer mortality are limited and based on studies on 4 different populations693
(Belgium, Sweden, The Netherlands and United States). Despite low statistical power, these studies694
demonstrate very few cancer events in the population of transgender men695
(30,85,94,104,132,148,149). The data on overall mortality in transgender men, specifically related to696
testosterone treatment, are scarce and the few available studies are underpowered (30). A study697
from the Dutch cohort with 122 transgender men (148), with a later follow-up on 293 (149) and 364698
transgender men (104), reported mortality to be similar to those of the general population. The lack699
of cancer outcome data underlines the need for studies of a large and inclusive sample size and long-700
term follow-up from multiple specialized centers.701
Other considerations702
Fertility703
There is a clear need to discuss reproductive option with transgender men, before starting704
testosterone treatment (99). From a study based on a questionnaire, 54% of the transgender men705
desired to have children and 37% would have banked oocytes, if this had been possible (150). Genital706
reconstructive surgery results in an irreversible loss of natural reproductive capacities, while707
testosterone therapy has an important, but partially reversible impact on fertility. In theory, embryo708
and oocyte cryopreservation as established techniques, and ovarian tissue cryopreservation more709
experimentally can be mentioned as examples of fertility preservation options (151). The necessary710
hormonal stimulation with multiple endovaginal ultrasound monitoring are likely to be perceived as711
physically and emotionally difficult, making oocyte cryopreservation not the preferred fertility712
preservation technique in this group and some wish to postpone this towards the time of713
hysterectomy and oophorectomy. A strong suppression of AMH has been described in 22714
transgender men treated with a GnRH agonist, combined with testosterone gel and an aromatase715
inhibitor (152). Reassuringly, androgen treatment did not deplete the primordial follicles in the716
ovarian cortex strips and a normal distribution of cortical follicles in the ovaries remained intact in 40717
transgender men after more than one year of testosterone treatment (153). However, the use of in718
vitro maturation without the use of xenotransplantation is far from implementation in a clinical719
setting (154). Once a mature oocyte is obtained, the use of partner sperm or donor sperm and a720
recipient uterus upon thawing of the oocytes, or a female partner or surrogate mother will enable721
conception.722
Based on an online survey in 41 transgender men who had been pregnant, of which 25 had used723
testosterone, 80% reported resuming menstruation within 6 months upon interrupting testosterone724
treatment, while 20% experienced no menses before pregnancy. Of note, exogenous testosterone is725
not an adequate mean of birth control. Testosterone has teratogen effects on the fetus; therefore726
transgender men should avoid pregnancy while on testosterone therapy. This is included in727
preconception counseling that addresses stopping testosterone while trying to conceive and during728
pregnancy, with the possibility of increasing gender dysphoria during and after the pregnancy.729
Postpartum the options for breast feeding and when to reinitiate testosterone have to be discussed730
(155).731
732
Monitoring of virilizing hormone therapy733
Monitoring is advised 3-4 monthly in the first year of treatment and 1 to 2 per year thereafter,734
according to the Endocrine Society Guidelines (40). Aiming at testosterone levels in the physiologic735
normal male range and measuring hematocrit or hemoglobin in order to avoid erythrocytosis are the736
most important parameters. Bone densitometry in transgender men should be performed if risk737
factors (smoking, excessive alcohol use, family history of osteoporosis, history of fracture, use of738
glucocorticoids, anorexia nervosa) for osteoporosis exist, and more specifically in those who stop or739
temporarily interrupt hormone therapy after gonadectomy. Screening for breast and cervical cancer740
in transgender men who do not undergo surgical interventions is advised (40).741
Insert fig. 2 about here742
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745
III. Hormonal treatment in adolescents746
The endocrine treatment of transgender adolescents consists of two phases: pubertal suspension or747
gonadal suppression followed by the addition of hormones. During the first phase (further) pubertal748
development is halted and adolescents can further explore their gender identity and prepare for the749
next phase.750
Gonadal suppression in adolescents751
Gonadal suppression using gonadotropin releasing hormone analogues (GnRHa)752
To achieve gonadal suppression generally gonadotropin releasing hormone analogues (GnRHa) are753
used (156). GnRHa have been used since 1981 in the treatment of central precocious puberty754
(157,158) and their benefits are well established and the use of GnRHa is regarded as both safe and755
effective, with no long-term adverse effects (159).756
Treatment can generally start when the adolescent is in Tanner stage 2-3. In clinical practice,757
transgender boys usually can start when in Tanner stage Breast 2 and transgender girls when they758
have a testicular volume of 6-8 ml. Also, adolescents who have already physically matured can use759
GnRHa to inhibit unwanted pubertal development, such as breast formation and menses in girls or760
further male phenotype development and erections in boys, until the adolescent’s gender identity is761
more stable (40).762
The general safety and efficacy of GnRHa have been studied (160,161). Anthropometry and body763
development, hormonal status and metabolic parameters were followed prospectively in 49764
transgender girls (median age at start 13.6 years, Tanner stage Genital 4) and 67 transgender boys765
(median age 14.2 years, Tanner Breast 4) during 12 months of GnRHa mono-therapy. Puberty was766
adequately suppressed with a decrease of testicular volume from 13.9 ml (± 6.5) to 8.6 ml (±4.7) in767
33 transgender girls. In transgender boys, who initiated GnRHa early in puberty at Tanner Breast 2768
and early menarche, breast tissue fully regressed to stage 1 (n=4) and menses ceased. Effective769
gonadal suppression was also reflected in a decrease in gonadotropins levels after a period of three770
months to nearly undetectable levels and a coinciding decrease in sex hormones. Testosterone771
decreased from 262 ng/dL (9.1 nmol/L) to lower than 29 ng/dL (1.0 nmol/L) in transgender girls. In772
transgender boys, estradiol decreased from a median of 123 pmol/L to 29 pmol/L. As for773
anthropometry, height velocity decreased in both transgender boys and transgender girls while BMI-774
SDS calculated for sex assigned at birth increased significantly. Body composition and the lean body775
mass percentage decreased and fat percentage increased significantly. Regarding safety monitoring,776
glutamyl transferase, AST, ALT and creatinine levels did not significantly change from baseline to 12777
months of treatment but alkaline phosphatase decreased, most likely reflecting the decrease in778
growth velocity (160).779
GnRHa is generally well tolerated with the exception of hot flushes early in treatment (161).780
However, hypertension in transgender adolescents under triptorelin treatment was reported in three781
transgender boys in a cohort of 138 subjects. Hypertension was reversible upon cessation of782
triptorelin but in one case increased intracranial pressure occurred, requiring the temporary use of783
acetazolamide (162). GnRHa induced hypertension is an uncommon side effect and has only been784
reported incidentally in children (163, 164).785
786
Gonadal suppression in adolescents using other regimes787
When resources cannot provide for GnRHa alternative treatment regimens should be considered788
such as progestagens in transgender boys or CPA in transgender girls(40). Similar to transgender789
women, endogenous androgen production can be suppressed using anti-androgens such as CPA or790
spironolactone in late pubertal girls. The effects of prolonged CPA mono-therapy were studied791
retrospectively in 27 transgender girls who were in Tanner Genital stage 4. After 6 months of CPA 50792
mg once daily testosterone decreased from 432 ng/dl (15.8 nmol/L) to 248 ng/dl (8.6 nmol/L) and793
remained stable at 226 ng/dl (7.8 nmol/L). LH and FSH however were not suppressed at 5.0 IU/L and794
5.1 IU/L during this period. Prolactin increased from 318.2 pmol/L to 760.8 pmol/L but none795
developed galactorrhea. Clinically more than half of the subjects reported reduced shaving frequency796
and in approximately one third had breast development (Tanner stage Breast 2-3). There was no797
increase in BMI-SDS. Fatigue was the only reported side effect. As for safety monitoring, only a798
transient increase of liver enzymes was seen in 15% of the study subjects. The levels remained under799
the threshold of three times the upper limit and therefore treatment was not stopped. Metabolic800
parameters such as lipid profile and glucose homeostasis were not negatively affected(165).801
In post-menarche adolescent transgender boys an alternative for GnRHa to stop or decrease menses802
frequency may be the use of progestagens. A cohort of 42 transgender boys (mean age of 15 years803
and in Tanner Breast 4) was retrospectively studied during 11.6 months of lynestrenol mono-therapy.804
After 6 months metrorrhagia occurred in 50% but reduced to 18% in the following 6 months.805
Subjects reported headache (12%) and hot flushes (10%). Serum LH decreased from 7.56 IU/L to 2.58806
IU/L but levels of FSH and estradiol remained unchanged. Weight increased during the first 6 months807
but returned to baseline value after 12 months. Regarding safety monitoring hemoglobin and808
hematocrit increased but remained in the normal male range. Liver enzymes, lipid profile and809
glucose homeostasis were not negatively affected(166).810
811
The addition of gender affirming hormones to GnRHa monotherapy812
Hormone therapy in adolescents generally has two treatment regimes. In the case when GnRHa813
treatment is initiated in the early stages of pubertal development, the “new” puberty is induced with814
a dosage scheme that is also common in hypogonadal patients. Alternatively, when GnRHa815
treatment is initiated in late puberty and thus the duration of the hypogonadal state was limited,816
hormones can be given at a higher initial dose and more rapidly increased until the expected adult817
dose. An additional advantage of GnRHa treatment is that hormones do not have to be administered818
in supraphysiological dosages, which would otherwise be needed to suppress endogenous sex819
steroid production (40).820
The timing of starting sex hormones in transgender adolescents continues to be an issue of debate.821
The recommended age of 16 years (40) is based on local jurisdiction, and not on cognitive822
maturation or pubertal development. In most countries at age 16 one is considered to be legally823
adult and one can make medical decisions. Indeed, when the first studied cohort was started in the824
Netherlands the age of 16 was chosen for this very reason. As a consequence there is little data825
available on starting GnRHa at an earlier age. The Endocrine Society guidelines make a826
recommendation to allow hormone therapy to be initiated at ages younger than 16 when the827
transgender child is evaluated by a multi-specialty team with expertise in gender identity828
development in children. However, the need for re-evaluating the recommended age for starting829
GnRHa may shift in the future (1).830
831
Transgender girls832
For a pubertal induction, it is recommended to start 17-beta estradiol at a dosage of 5 mg/kg/day,833
followed by 6 monthly increments of 5 mg/kg until a maintenance dosage of 2 mg is reached. The834
second treatment regime is more suitable for transgender girls who initiated gender affirming835
treatment when at least 15.5 years old. After a period of gonadal suppression varying from 3 to 6836
months, estrogens can be given at a daily start dosage of 1 mg and increased to 2 mg after 6 months837
(40).838
The effects of the addition of 17-beta estradiol were studied prospectively in 28 transgender girls839
(158). Estrogen treatment was started at a median age of 16.0 years after median duration of 24.8840
months of GnRHa mono-therapy. Breast development had started within 3 months and after 1 year841
median Tanner breast stage was 3 progressing to 5 after 3 years (n=16) with a variability of all breast842
stages. With respect to body shape, hip circumference increased and waist circumference decreased.843
Although BMI increased, BMI-SDS did not. When bone age was < 15 years at the start of estradiol,844
median height gain was 6.8 cm after 3 years of estrogen therapy. Overall final height was 182.7 cm845
corresponding to +1.9 SD for Dutch adult women. When the adult dose of 2 mg estradiol daily was846
used during a median duration of 2 years the median serum estradiol was 27 pg/mL (100 pmol/L)847
(range, 6,5-103 pg/mL (24 to 380 pmol/L). A change in prolactin levels was not seen. In addition,848
hemoglobin, hematocrit, HbA1c, liver enzymes and creatine remained unchanged (167).849
Transgender boys850
For pubertal induction the use of testosterone-esters injections is recommended. The initial dose is851
25 mg/m2 every two weeks IM; and is increased with 25 mg/m2 every 6 months. The maintenance852
dosages vary from 200 mg per two weeks for testosterone mono-esters, such as testosterone853
enanthate, to 250 mg per 3-4 weeks for testosterone esters mixture. For transgender boys who854
started treatment in late puberty, testosterone can be started at 75 mg IM every two weeks,855
followed by the maintenance dosage after 6 months(40). It is advised to continue GnRHa at least856
until maintenance dosage of testosterone is reached and preferred to continue until gonadectomy.857
With androgens, virilization of the body occurs: lowering of the voice, more muscular development,858
particularly in the upper body, facial and body hair growth and clitoral growth(40,161).859
Other considerations860
Bone health in transgender adolescents861
During puberty the bone mass increases and peak bone mass is only achieved at the age of 20-30862
years (168). Bone mass accrual is regulated by genetic factors, gonadal hormones, and863
environmental factors such as physical activity and adequate supply of nutrients (calcium, vitamin D).864
During the hypogonadal state induced by GnRHa mono-therapy bone mineral density (BMD) is865
affected(170-171). In transgender girls BMD of the lumbar spine remained stable but Z-score866
decreased during 1.5-2 years of gonadal suppression. In the femoral region BMD and Z-score867
decreased but not significantly. In contrast, in transgender boys the BMD of lumbar spine and868
femoral region decreased together with the corresponding Z-scores(170).869
When sex steroids are added, bone mass accrual reassumes. In transgender girls, absolute BMD and870
Z-scores in the lumbar spine but not the hip increased (170,171) but after two years of estrogen their871
Z-scores were still below that of age- and sex assigned-matched norms (171). In transgender boys872
(153,154), the bone density and Z-scores of the lumbar spine and the femoral region increased873
(n=42) after 2 years of testosterone therapy but were still not at pretreatment level (171).874
When BMD development was assessed until young adulthood, however, it was found that the loss in875
Z-score was still partially present at the age of 22 implying a possible delay in or loss of peak bone876
mass(170). To this date only one case report has been published on long term BMD development and877
it was shown that absolute BMD and Z-scores of a transgender man, treated with GnRHa in his878
adolescence was in the normal range at age 35. However pre-treatment data was not provided(172).879
880
The addition of gender affirming hormones to other methods of gonadal suppression881
Transgender girls882
Two retrospective studies reported on the addition of estrogens to anti-androgen therapies in883
transgender adolescents. In one study the subjects received CPA (165) and in the other study884
spironolactone (79) was used. The addition of estrogens to CPA mono-therapy in transgender girls885
resulted in either the initiation or further progression of breast development. Oral 17-beta estradiol886
was started at 0.5 mg daily and increased to 0.75 mg after 6 months. After 12 months of estrogen887
therapy 66.7 % reached Tanner Breast 3 and 9.5% reached Tanner Breast 4. After 12 months, both888
testosterone and LH decreased significantly to 168 ng/dl (5.8 pmol/L) and 3.2 IU/L, respectively and889
FSH demonstrated a declining trend to 2.8 IU/L. The mean 17-beta estradiol level was 33 pg/mL890
(121.1 pmol/L). The most common adverse event reported by the transgender girls was fatigue but891
resolved in almost all. BMI-SDS remained stable. In addition metabolic parameters, lipid profile and892
glucose homeostasis did not change(165).893
In a study of 44 transgender girls (mean age 18 years; range 14-25) of whom 38 received894
spironolactone (dosage 50 -200 mg daily) oral estrogen was added in three routes, oral (dosage895
between 1 to 8 mg daily), intramuscular (dosage 20 to 80 mg monthly) or transdermal (dosage 0.025896
to 0.200 mg weekly). There were no changes reported in BMI, metabolic parameters, lipid profile and897
prolactin and there were no differences in the methods of administration. Among the 38 subjects898
taking spironolactone potassium levels did not change(79).899
900
Transgender boys901
Testosterone can be added to progestagens as previously described (40) The clinical effects and902
effects on metabolic parameters in adolescent transgender boys have been investigated903
retrospectively in two studies, one single center study (n=42)(166) and one multicenter study center904
(n=72)(79); albeit in the later study 7 subjects had received GnRHa prior to the testosterone therapy.905
Only the single center study reported on side effects, which were fatigue and acne. Clinically, there906
was a weight gain as both BMI (79) and BMI-SDS increased (166). Although testosterone preparation907
and dosing differed, both studies reported an increase in both hemoglobin and hematocrit. With a908
testosterone-ester mixture on a biweekly frequency, values remained within the normal male909
range(166), whereas when treated with testosterone-ester on a weekly base, hematocrit increased910
to supraphysiological levels of above 50% in 3% of the cohort (2 cases) with no adverse events911
reported(79). ALT, AST, creatinine increased but remained in the normal range. Lipid profile was912
more unfavorable with an increase of cholesterol and LDL and a decrease of HDL. Glucose913
homeostasis parameters HbA1c (79,166) and insulin, glucose, or HOMA index (157) were not914
affected.915
916
Final considerations917
Knowledge regarding the treatment of gender dysphoria and non-conforming has steadily advanced918
over the past 10 years (173). While the psychological benefits of gender affirming treatment for919
young adolescents with gender dysphoria using GnRHa have been established(174,175), data on long920
term health outcome are still sparse. GnRHa treatment in adolescents is both clinically and921
biochemically effective in suppressing the hypothalamic-pituitary-gonadal axis and appears to be922
well tolerated and safe(160). However, transgender boys may be more susceptible for the923
development of arterial hypertension(162). Studies regarding treatment with estrogen on pubertal924
development and short-term safety demonstrate feminization of the body without adverse events925
(167). In transgender boys, data on combined GnRHa and androgens is lacking. Retrospective reports926
on bone mineral density development demonstrated a loss of Z-scores in transgender boys and927
transgender girls during gonadal suppression, followed by an increase after the addition of hormones928
but at the age of 22 years Z-scores were still under pretreatment-level. Other long-term follow-up929
data is not available. Also the afore mentioned studies mainly describe a relatively older and mature930
group, mid-teens and Tanner 4 and up, which coincides with a relatively shorter duration of an931
induced hypogonadal state. There are currently no publications available focusing on treatment of932
the young and less matured (Tanner 2 or 3) adolescent with gender dysphoria and therefore the933
effects of prolonged gonadal suppression i.e. 3 to 4 years; short- or long-term are unknown. There934
needs to be investigation if the initiation of sex steroid hormones before the recommended age of 16935
may prevent the negative sequelae of hypogonadism on the skeleton. Finally, when GnRHa are not936
available, alternative methods to suppress puberty can be used in the more sexually matured937
adolescent. Short-term data on the use of anti-androgens in transgender girls and progestagens in938
transgender boys demonstrated its efficacy and safety(165,166).939
940
941
942
Key Conclusions and Recommendations for Future Clinical Research943
The current available research is based mostly on cross-sectional studies, with limited longitudinal944
data. There is also paucity of information on diverse ethnic and socioeconomic populations and945
papers on treatment outcome in adolescents. The current literature comes from mostly Western-946
European and from higher income countries, where many participants undergo surgical procedures,947
and has at best intermediate duration follow-up. Limited data exists on the hormonal treatment in948
gender non-binary persons. For specific analyses such as outcome or mortality, no single center has a949
sufficiently large patient base to study the population with statistical rigor.950
An important barrier to better care is the diversity of training and practice across providers. Health951
care professionals continue to face challenges in providing optimal care for the transgender952
population, also due to a lack of education on the topic. The improvement of formal transgender953
education in medical schools and among health care providers in the broadest sense is timely (176).954
Professionals working in health services need to understand that patients’ gender identity is important955
and needs to be considered during any consultation. Treating people with respect requires a good956
understanding of people’s identity regarding their gender. Transgender health care has to be included957
in national and international conferences of all involved specialties. We feel strong about the fact that958
involving the transgender community at all stages of research is vital. This patient-centered research959
will progressively lead towards more studies where transgender community involvement is crucial in960
identifying research priorities, research design, helping recruitment, dissemination of study results.961
Patient centered outcome priorities in endocrinology are breast development in transgender women,962
time to menstrual cessation in transgender men, dose-related responses to hormonal interventions,963
effect on sexual function and fertility among many others (177).964
Transgender medicine research is finally moving away from case reports and small series. Many965
efforts have gone into summarizing available data in numerous recent systematic reviews, from966
which we have to internalize the findings, avoid repeating the same research, and take the967
investigations further. The collection and reporting of original good quality data through networks968
has to be higher on the agenda. Innovative and patient-centered long-term research with969
randomized controlled trials if possible, to advance of the safety and efficacy of hormonal970
interventions is a priority. In doing so, clinicians and academics must listen to the voices of971
transgender people, recognizing and respecting the internal diversity within the transgender972
community.973
974
975
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Table 1: Terminology used in transgender health1513
Cisgender- A person whose identity matches the sex assigned at birth.
Gender affirming treatment- Physical treatment that some transgender people access in order for
their bodies to be adapted to the bodies of their experienced gender or gender identity by means of
hormones and/or surgery.
Gender dysphoria- A profound distress or discomfort caused by the discrepancy between assigned
sex at birth and gender identity. This is the same term as the current diagnostic term of the DSM-5.
Gender expression- The external manifestations of someone’s gender, which can include name,
pronouns, clothing, haircut, behavior, voice, or body characteristics.
Gender identity / experienced gender- A person's internal sense of gender. Unlike gender expression,
gender identity is not visible to others.
Gender identity disorder- Diagnostic term used in previous versions of the DSM. The term is still used
for the child diagnosis in the ICD-10, but the proposed name for ICD-11 is gender incongruence of
childhood. Currently this term is not preferred given the term “disorder”.
Gender Incongruence- The proposed diagnostic term to be used in the new edition of the ICD-11. Not
all individuals with gender incongruence have gender dysphoria or seek gender-affirming treatment.
Gender reassignment- Previously used term to describe what is known now as gender-affirming
treatment.
Gender role- The behaviors, attitudes, and personality traits that a society, in a historical period,
designates as masculine or feminine.
Natal sex- The term “sex assigned at birth”, which is usually based on genital anatomy, is more
appropriate.
Sex- Attributes that characterize biological maleness or femaleness. They can include the sex-
determining genes, the sex chromosomes, the H-Y antigen, the gonads, sex hormones, internal and
external genitalia and secondary sex characteristics.
Sexual orientation - An individual's physical and emotional attraction to another person. Gender
identity and sexual orientation are not the same. Irrespective of their gender identity, transgender
people may be attracted to women (gynephilic), attracted to men (androphilic), or be bisexual,
asexual, pansexual, etcetera.
Transgender (adj.) - An umbrella term to describe individuals, whose gender identity differs from the
sex assigned at birth based on their sexual characteristics.
Transgender male - A person whose sex was assigned female at birth (based on their sexual
characteristics) but self-identifies as male.
Transgender female - A person who self-identifies as female, but whose sex was assigned male at
birth.
Transition - The process during which transgender people change their physical, social, and/or legal
characteristics consistent with their gender identity.
Transsexual (adj.)- A diagnostic term used in the ICD-10. The term is currently used in some of the
medical literature when discussing diagnoses. The term transgender should now be used instead
except when referring to the current ICD-10 diagnosis.
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Figure 11519
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Effects of estrogen and antiandrogen treatment in transgender women, reproduced with permission1521
from (41)1522
Figure 21523
Effects of testosterone treatment in transgender men, reproduced from (112)1524
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